How Efficacious is Danshen (Salvia miltiorrhiza) Dripping Pill in Treating Angina Pectoris? Evidence Assessment for Meta-Analysis of Randomized Controlled Trials

2017 ◽  
Vol 23 (9) ◽  
pp. 676-684 ◽  
Author(s):  
Yongliang Jia ◽  
Siu-wai Leung
Keyword(s):  
Angina Pectoris ◽  
Randomized Controlled Trials ◽  
Salvia Miltiorrhiza ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Randomized Controlled

scholarly journals Meta-Analysis of Randomized Controlled Trials on the Efficacy of Di’ao Xinxuekang Capsule and Isosorbide Dinitrate in Treating Angina Pectoris

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Yongliang Jia ◽  
Cong Chen ◽  
Choi-San Ng ◽  
Siu-Wai Leung
Keyword(s):  
Sensitivity Analysis ◽  
Angina Pectoris ◽  
Randomized Controlled Trials ◽  
Isosorbide Dinitrate ◽  
Subgroup Analysis ◽  
Meta Analysis ◽  
Effect Sizes ◽  
Controlled Trials ◽  
Randomized Controlled ◽  
Study Characteristics

Objective. Randomized controlled trials (RCTs) on di’ao xinxuekang capsule (XXK) in treating angina pectoris were published only in Chinese and have not been systematically reviewed particularly for comparing XXK with isosorbide dinitrate (ISDN). This study aims to provide a comprehensive PRISMA compliant and internationally accessible systematic review and meta-analysis to evaluate the efficacies of XXK and ISDN in treating angina pectoris.Methods. The RCTs published between 1989 and 2011 on XXK and ISDN in treating angina pectoris were selected according to specific criteria. Meta-analysis was performed to evaluate the symptomatic (SYMPTOMS) and electrocardiographic (ECG) improvements after treatment. Odds ratios (OR) were used to measure effect sizes. Subgroup analysis, sensitivity analysis, and metaregression were conducted to evaluate the robustness of the results.Results. Seven RCTs with 550 participants were eligible. Overall ORs for comparing XXK with ISDN were 4.11 (95% CI :  2.57, 6.55) in SYMPTOMS and 2.37 (95% CI : 1.46, 3.84) in ECG. Subgroup analysis, sensitivity analysis, and metaregression found no significant dependence of overall ORs upon specific study characteristics.Conclusion. The meta-analysis of eligible but limited RCTs demonstrates that XXK seems to be more effective than ISDN in treating angina pectoris. Further RCTs of high quality are warranted to be conducted for update of the results of this meta-analysis.

scholarly journals The Efficacy of Guanxinning Injection in Treating Angina Pectoris: Systematic Review and Meta-Analysis of Randomized Controlled Trials

2013 ◽  
Vol 2013 ◽  
pp. 1-16 ◽  
Author(s):  
Yongliang Jia ◽  
Siu-wai Leung ◽  
Ming-Yuen Lee ◽  
Guozhen Cui ◽  
Xiaohui Huang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Sensitivity Analysis ◽  
Angina Pectoris ◽  
Randomized Controlled Trials ◽  
Subgroup Analysis ◽  
Meta Analysis ◽  
Controlled Trials ◽  
Eligibility Criteria ◽  
Randomized Controlled ◽  
Study Characteristics

Objective. The randomized controlled trials (RCTs) on Guanxinning injection (GXN) in treating angina pectoris were published only in Chinese and have not been systematically reviewed. This study aims to provide a PRISMA-compliant and internationally accessible systematic review to evaluate the efficacy of GXN in treating angina pectoris.Methods. The RCTs were included according to prespecified eligibility criteria. Meta-analysis was performed to evaluate the symptomatic (SYMPTOMS) and electrocardiographic (ECG) improvements after treatment. Odds ratios (ORs) were used to measure effect sizes. Subgroup analysis, sensitivity analysis, and metaregression were conducted to evaluate the robustness of the results.Results. Sixty-five RCTs published between 2002 and 2012 with 6064 participants were included. Overall ORs comparing GXN with other drugs were 3.32 (95% CI: [2.72, 4.04]) in SYMPTOMS and 2.59 (95% CI: [2.14, 3.15]) in ECG. Subgroup analysis, sensitivity analysis, and metaregression found no statistically significant dependence of overall ORs upon specific study characteristics.Conclusion. This meta-analysis of eligible RCTs provides evidence that GXN is effective in treating angina pectoris. This evidence warrants further RCTs of higher quality, longer follow-up periods, larger sample sizes, and multicentres/multicountries for more extensive subgroup, sensitivity, and metaregression analyses.

Sign in / Sign up

Export Citation Format

Share Document